ライフサイエンスコーパス: white cell count

1 1 are older (median age 9 years), with a low white cell count.

2 itution of chemotherapy and normalization of white cell count.

3 io of FLT3-ITD to wild-type FLT3 and for the white-cell count.

4 linical examinations, hemoglobin levels, and white cell counts.

5 t 60 h, through comparable CSF bacterial and white cell counts.

6 o, the S. typhi vaccination caused a rise in white cell count (11.1 +/- 0.5 x10(9)/l vs. 7.9 +/- 0.8

7 wice the upper limit of normal (2N) or more, white cell count 150 x 10(9)/L or more, abnormal chromos

8 White cell count (16.2 +/- 10.5 v 6.9 +/- 3.5 (x 109/L);

9 ducing the time of return to normalcy of the white cell counts after chemotherapy in patients with ac

10 Laboratory studies revealed a normal white-cell count, an international normalized ratio of m

11 inine, haemoglobin, potassium, sodium, urea, white cell count and an index NEWS undertaken within +/-

12 d with steroid withdrawal were reductions in white cell count and haemoglobin and increases in plasma

13 aminotransferase (ALT), blood pressure, and white cell count and lower HDL cholesterol compared with

14 0.83 (0.73, 0.94) and 0.81 (0.69, 0.93) for white cell count and platelet count respectively.

15 Vaccination resulted in elevations in white cell count and serum levels of interleukin-6 and i

16 model identified age, NEWS, albumin, sodium, white cell count and urea as significant (p<0.001) predi

17 patients present at diagnosis with increased white cell counts and hepatosplenomegaly, and are at an

18 White cell counts and plasma lipoprotein profiles were s

19 cerebrospinal fluid comprising either raised white cell counts and/or raised levels of interferon-alp

20 e analysis that was adjusted for the initial white-cell count and the day of illness on which stool w

21 ate analysis with cytogenetic category, age, white cell count, and French-American-British subtype de

22 Serum fibrinogen, white cell count, and high-sensitivity C-reactive protei

23 status, high fungal burden, high peripheral white cell count, and older age.

24 ing and beta(2)M, hemoglobin, prior therapy, white cell count, and platelet level (P =.005).

25 type, and Ho-Tr was independent of sex, age, white cell count, and T-cell status among Ph-negative pa

26 transport variables, total and differential white cell counts, and serum concentrations of TNF and I

27 Levels of C-reactive protein, the white-cell count, and fibrinogen levels were strong pred

28 The fetal hemoglobin level, white-cell count, and platelet count and the use of hydr

29 Multivariate analysis incorporating age, white-cell count, and treatment parameters showed that s

30 CRLF2-d was not associated with age, sex, or white cell count, but IGH@-CRLF2 patients were older tha

31 elet count and hematocrit in addition to the white cell count during the first 3 months of therapy wi

32 n activator antigen, C-reactive protein, and white cell count, even after adjustment for possible con

33 s, LDL cholesterol, HbA(1c) (A1C), increased white cell count, ever having smoked, and previous retin

34 d glucose >150 mg/dL (8.2 mmol/L), admission white cell count >14,300 cells/mm3 (14.3 x 10(9) cells/L

35 In a murine MPN model, CYT387 normalized white cell counts, hematocrit, spleen size, and restored

36 lammation at 8 hours, reflected by increased white cell count in both sexes.

37 We determined differential white cell counts in peripheral blood of 189 adults who

38 clinical signs of encephalitis had elevated white cell counts in the blood caused mostly by increase

39 ong patients with AML, independently of age, white-cell count, induction dose, and post-remission the

40 he prognostic significance of the presenting white cell count is weaker and the rate of decline in mi

41 arge were body mass index less than 28 kg/m, white cell count less than 15,000/mL, C-reactive protein

42 ate >90/minute, respiratory rate >20/minute, white cell count <4 x 10(9)/L or >/= 20 x 10(9)/L, album

43 APL classified as low-to-intermediate risk (white-cell count, </=10x10(9) per liter).

44 (median 9 years vs 5 years), and had a lower white cell count (median 3.9 vs 12.4) compared with chil

45 and symptoms together with laboratory tests (white cell count, neutrophil count and C-reactive protei

46 dverse event in the entire cohort included a white-cell count of 200,000 per cubic millimeter or high

47 that fever, a virus-specific rash, and a CSF white-cell count of 5/microL or more were independent pr

48 ts one to nine years of age, all of whom had white-cell counts of at least 50,000 per cubic millimete

49 ALL who were either 1 to 9 years of age with white-cell counts of at least 50,000 per cubic millimete

50 The median cerebrospinal fluid white-cell count on the first lumbar puncture among pati

51 outcome, but either high cerebrospinal fluid white-cell counts or severe hyponatremia did.

52 specialty (medical versus surgical), raised white cell count, or co-morbidity.

53 Mutations were associated with a high white cell count (P =.006) and patients with inv(16) (P

54 to age, neutrophil JAK2 V617F allele burden, white-cell count, platelet count, or clonal dominance.

55 Decreases in white cell count, platelets and C-reactive protein were

56 olytic-uremic syndrome were a higher initial white-cell count (relative risk, 1.3; 95 percent confide

57 specific effects on mortality and neutrophil/white cell counts (rho = 0.48), C-reactive-protein (rho

58 al antibodies) was 67.9%, whereas normal CSF white cell counts ruled out Lyme neuroborreliosis with a

59 of C-reactive protein (CRP), fibrinogen, and white cell count to components of IRS in the nondiabetic

60 was consistent with meningitis or if the CSF white cell count was >100 cells/mm(3) (>50% neutrophils)

61 Increased circulating white cell count was associated with increased neutrophi

62 rticipants with early ART initiation had CSF white cell count (WCC) >/=5/microL at day 14 (58% vs 40%

63 Mean C-reactive protein (CRP), and white cell count (WCC) were significantly higher in the

64 sedimentation rate (ESR), hemoglobin, total white cell count (WCC), estimated glomerular filtration

65 eactive protein, platelet aggregability, and white cell counts were not modified by losartan.

66 tive protein, and fibrinogen levels, and the white-cell count were measured at base line, along with

67 ACLF grade and white cell count, were independent predictors of mortali

68 ic utility of quantifying the synovial fluid white cell count, with two recent systematic reviews rea